Google
ERNAW Stock Price & Analysis — Ernexa Therapeutics Inc. Warrants
ERNAW FAQ
What is ERNAW's dividend yield?
Ernexa Therapeutics Inc. Warrants offers a dividend yield of 0.00%.
Is now a good time to buy ERNAW?
Our AI Timing Score for ERNAW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
ERNAW AI Analysis Summary
Our AI summary for ERNAW: Ernexa Therapeutics Inc. Warrants (NASDAQ). The stock currently trades at a P/E of 0.00, a dividend yield of 0.00%. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.04
Price
-0.03
(-38.43%)
Day Change
|
|
|---|
Not enough data to analyze.
Loading chart...
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.04 |
| PBV / Sector |
0.01 / N/A
GREAT
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
774.783875000000
|
| Average 1W Daily Value |
307.566340000000
|
| Timing Factors |
|
42% |
| Financial Health |
|
% |
| Ability to Make Profit |
|
% |
| Return to Investors |
|
% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1035 Cambridge Street, Cambridge, MA, United States, 02141
Phone: 617 798 6700
Website: https://www.ernexatx.com
Sector: -
Description: Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
